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ABSTRACT RET/PTC is a transforming seque cated
by the fusion of the tyrosine inase domain of theRET protoon-
cogene with the 5' end of the locus DIOS170 dI by probe
H4 and is frequently found activated in human papillary thyroid
carcinomas. RET and DIOS)70 have been mappe to us
region of the long arm of chromosome 10: qll.2 and q21,
respectively. To identify the mechanis leadin to the generation
ofthe oncogenic seqe RET/PTC, a combined cytogenetic and
molecular analysis of several cas of papillary thyroid cadno-
mas was done. In four cases the results ted that these tumors
had RET/PTCactivatlon and a paracentric inversion of the long
arm of chromosome 10, inv(lO)(qll.2q21), with breakpoints
coinddent with the regions where RET and DIOSi70 are located.
Therefore, a chromosome lOq inversion provides the stural
basis for the DIOS170-RET fusion that forms the hybrid trans-
form sequence RET/PTC.
In some forms of cancer, chromosome rearrangements have
provided the structural basis of their molecular pathogenetic
mechanisms. In particular, in hematologic malignancies,
chromosomal translocations result in deregulation of the
expression ofthe cell-growth-related genes c-MYC and BCL2
in Burkitt and in follicular lymphomas, respectively (1-3). In
other instances, the translocation may generate chimeric
transforming transcripts as in the case of the BCR-ABL
fusion protein found in chronic myelocytic leukemia (4).
In solid tumors, however, only rarely have chromosome
aberrations been analyzed at the molecular level. The most
relevant examples include the chromosomal deletions found
to inactivate one or both copies oftumor-suppressor genes-
such as RB in retinoblastoma, WTI in Wilms tumor, andDCC
in colon carcinoma (5).
The only example of generation of chimeric transforming
sequences in solid tumors is tie activation of c-MET on
chromosome 7 by the TPR gene that maps to chromosome 1
(6). However, this event, most likely a chromosomal trans-
location, has been generated in vitro by treatment of the
original human osteogenic sarcoma cell line (HOS) with a
chemical carcinogen (7). In other cases the rearrangements
giving rise to the transforming fusion products have been
generated during the transfection procedures, as in the case
ofRET (8, 9). When a similar genetic event occurred somat-
ically in the original tumor DNA, like the fusion between the
nonmuscle tropomyosin sequence and the tyrosine kinase
domain ofproto-TRK gene (10), no chromosomal aberrations
were identified to provide a model for the relative mecha-
nism.
We have reported (11) the occurrence in papillary thyroid
carcinomas of specific rearrangements of the tyrosine kinase
domain of the proto-RET gene with an unknown "gene"
DJOS170, identified by probe H4 and originally designated
the chimeric transforming sequence as PTC11, but here des-
ignate it as RET/PTC. In two distinct sets of experiments,
RET/PTC activation was found in =25% of papillary thyroid
carcinomas (12, 13) and represented a tumor-specific somatic
event, being detected in the original DNA of both primary
tumors and metastases but not in normal cells from the same
patients (12, 13). We have mapped DIOSi70 to chromosome
10q21 (14, 15) and confirmed the RET locus at 10qll.2 (15,
16).
From one ofour laboratories (R.B.J., M.A.H., and I.D.H.)
the occurrence ofa simple cytogenetic aberration in papillary
thyroid carcinomas has also previously been reported: an
inv(10)(qll.2q21) (17) with breakpoints where RET and
DIOS170 are located. Among 18 cases of this tumor histo-
type, we have, to date, identified five cases that have this
identical abnormality. Here we report the cytogenetic and
molecular characterization of four of these tumors and dem-
onstrate that the cytogenetic inversion has provided the
structural basis for the DIOS]70-RET fusion leading to the
generation ofthe chimeric transforming sequence RET/PTC.
MATERIALS AND METHODS
Chromosome Preparation. Specimens from primary tumor
or metastatic lymph nodes were obtained at surgery and were
histologically diagnosed as papillary thyroid carcinomas.
Cases 1, 3, and 4 corresponded to pure papillary thyroid
carcinomas; case 2 might be considered a diffuse sclerosing
variant of papillary carcinoma. The samples were mechani-
cally disaggregated and incubated in 0.8% collagenase type II
(Sigma) at 370C in 5% CO2 overnight. The cell suspension was
seeded and cultured in RPMI 1640 medium (Whittaker Bio-
products) supplemented with 5% fetal calf serum (Flow
Laboratories), penicillin (200 units per ml), streptomycin (200
Ag/ml), transferrin (10 jug/ml), hydrocortisone (0.5 ,ug/ml),
epidermal growth factor (5 ng/ml) (Sigma), and insulin (5
,tg/ml) (Sigma).
IIPTC, the symbol used originally to designate this papillary thyroid
carcinoma transforming sequence, has another meaning (phenyl-
thiocarbamide tasting) for the Human Gene Mapping Nomenclature
Committee; the papillary thyroid carcinoma transforming sequence
is designated RET/NPC.
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Chromosome preparations were performed on primary
culture of 10 days, according to standard techniques. G-band-
ing was obtained by using Wright's stain.
Southern and Northern (RNA) Blot. High-Mr DNA was
digested with the appropriate restriction enzymes, electro-
phoresed, blotted on nitrocellulose or nylon filters, and
hybridized to nick-translated molecular probes, as described
(11).
Northern blot analysis used 10 Ag of total mRNA prepared
from the cell lines indicated in Fig. 3 and was done following
described procedures (11) by using as a probe a cDNA
fragment corresponding to the tyrosine kinase domain of the
RET oncogene (probe C3 of ref. 11).
Transfection Assay. The transfection assay was done on
NIH 3T3 cells with high-Mr DNA obtained from the meta-
static lymph node of patient 1, by following described tech-
niques (13).
PCR. RNA amplification was obtained by following the
method described by E. S. Kawasaki (18) starting from 1.5 ttg
of total mRNA. The map in Fig. 4 indicates the nucleotide
position of the primers related to DIOS170 (196-213) and RET
(485-502) sequences, respectively. The breakpoint of the
RET/PTC sequence between nucleotides 351 and 352 and the
EcoRI site (371) are also indicated.
RESULTS
The cytogenetic analyses of the tumor cells revealed as the
specific acquired abnormality a paracentric inversion of the
long arm ofchromosome 10 with breakpoints at qll.2 and q21
in 15 out of 15 metaphases of case 1, 8 out of 10 metaphases
of case 2, 3 out of 30 metaphases of case 3, and 29 out of 30
metaphases of case 4. Fig. 1A shows a representative exam-
ple of the inversion from patients 1 and 2. An identical
inversion was seen in patients 3 and 4. The karyotype of
patient 4 has been reported in detail elsewhere (17). The
peripheral lymphocytes of patients 1, 2, and 4 showed a
normal 46,XX karyotype. The peripheral lymphocytes of
patient 3 were not studied.
The rearrangement of the RET gene, leading to the gener-
ation ofRET/PTC has been shown to occur in a 6.3-kilobase
(kb) EcoRI fragment of the proto-RET gene located imme-
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FIG. 1. Chromosome 10q inversion in papillary thyroid carci-
noma. (A) Two representative chromosome 10 homologs from tumor
cells of patients 1 and 2 showing inv(10)(qll.2q21) (arrows). (B)
Schematic view of the paracentric inversion of chromosome lOq
generating the transforming sequence RET/PTC. The gene order on
chromosome lOq has been previously determined (16). The indicated
direction of gene transcription is one of the two possibilities (diver-
gent vs. convergent).
diately upstream of its tyrosine kinase-encoding domain,
whereas DIOS]70 truncation was found at different points in
different tumors (11). The DNA from the four tumors carry-
ing the lOq inversion was analyzed by Southern blot with a
1-kilobase pair (kbp) Bgl II-BamHI probe (Fig. 2, probe 2),
specific for the 6.3-kbp EcoRI fragment of proto-RET, where
all the characterized RET rearrangements have been dem-
onstrated. The probe detected an extra band in the four
tumors and not in the related normal DNA (Figs. 2 and 3A),
indicating the tumor-specific RET activation (11). To dem-
onstrate the involvement of DJOS170 sequences in the RET
rearrangement of the four tumors, we analyzed their DNAs
with the available DIOS] 70-specific Alu-free genomic probes.
In patients 2 and 3 using the 0.6-kbp BamHI-Ava I DIOS170
probe (Fig. 2, probe 3) a rearranged band was clearly detected
(Fig. 2). In patient 3 the 6-kbp BamHI-rearranged DIOS170
band was of the same size as one of the BamHI-rearranged
RET bands. This finding indicates that the two genes are
fused together. In cases 1 and 4 we were unable to show a
DIOSJ70 rearrangement (Fig. 3B and data not shown). How-
ever, because case 1 provided enough tumor tissue, a trans-
fection assay on NIH 3T3 cells was done. After 14 days 1.05
foci per Ag ofDNA was observed. The NIH 3T3 transform-
ants possessed both human RET (Fig. 3A, lane NIH-T1) and
DIOSJ70 (Fig. 3B, lane NIH-T1) sequences. As expected, the
human DIOSJ7O and RET sequences detected in the trans-
formants were of the same size as the DJOSJ70-related
fragment and the RET-rearranged band present in the original
tumor DNA (Fig. 3A, lane T). As anticipated, the size of the
DIOS] 70 fragments was not distinguishable from that of the
DIOSI 70 fragment seen in normal DNA (Fig. 3B). Moreover,
Fig. 3D shows a Northern blot obtained with a RET-specific
cDNA probe; in the transformants obtained with DNA from
this tumor, the RET oncogene was transcribed in truncated
mRNAs having sizes identical to those previously detected in
a RET/PTC-positive papillary thyroid carcinoma (11). Tran-
scripts of the same size were detected in the same cell lines
with a DJOSJ70-specific probe (data not shown). A PCR
analysis was performed with primers derived from both the
RET and the DJOSJ70 portion of RET/PTC to amplify a
cDNA fragment that contained the RET-DIOSI 70 breakpoint
(11) (Fig. 4). This experiment showed that the RET-DIS0170
rearrangement, although occurring in different intronic re-
gions, produced identical mRNA species. In fact, the RET/
PTC cDNAs derived from NIH 3T3 transfectants of the case
reported (11) and from the tumor ofcase 1 contained the same
predicted fragment of 306 base pairs. Complementary DNA
directly prepared from the tumor of patient 1 contained the
same PCR fragment (Fig. 4), thus confirming RET/PTC
activation. The specificity of the amplified bands was ascer-
tained by EcoRI digestion of the PCR products that resulted
in the predicted fragments (Fig. 4, bands A and B). The same
result was also obtained in patient 3, confirming the above
conclusions (data not shown); moreover, the specificity of
the PCR was ascertained by hybridizing its products with
PTC-specific probes and by sequencing the PCR products
(data not shown).
The cytogenetic and molecular genetic data indicate that an
inversion on chromosome lOq has activated RET/PTC by
fusing together DIOSJ70 and RET sequences. Such a mech-
anism would predict that in tumor DNA the sequence of the
RETgene located upstream from the breakpoint is rearranged
and fused to the 3' end sequence of DIOSJ70. The tumor
DNAs from the four patients were analyzed with a probe
located upstream from the breakpoint in the proto-RET gene
(Fig. 2, probe 1), and an extra band was detected demon-
strating that the 5' end of proto-RET was rearranged in all
these cases (Figs. 2 and 3C).
Moreover, in patients 2 and 3, we detected a rearranged band
of the same size, 10.5 kbp and 7.2 kbp, respectively, with both
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FIG. 2. Southern blot analysis of normal (peripheral blood cells) (lanes N) and tumor (lanes T) DNA of patients 2, 3, and 4 with papillary thyroid
carcinomas displaying inv(10Xq1l.2q21). The analysis was done after digestion with the indicated restriction enzymes and by using as probes: (i) a 1-kb
Bgl II (Bg)-BamHI (B) probe specific for the 6.3-kbpEcoRl (E) fragment ofproto-RET(probe 2); (ii) a 0.6-kb BamHl-Ava I (A) DIOS170 fragment (probe
3) for patients 2 and 3, for patient 3 also aO.6-kbBamHl-EcoRI DJOS17O-specific sequence (probe 4); and (iii) a 1.8-kbpBamHI-BamHI fragment related
to the 5' end of proto-RET (probe 1). Size of normal and of rearranged (arrows) bands is given as kbp.
3'-end DIOS]70 and 5'-end proto-RET-related probes (Fig. 2).
This band represents the fusion event reciprocal to that gener-
ating the RET/PTC oncogenic sequence (see Fig. 1B).
DISCUSSION
Oncogene activation by chromosome rearrangements has
been described in some hematopoietic malignancies (1, 2, 4).
The cytogenetic and molecular analyses of the four cases of
papillary thyroid carcinomas reported here provide an example
of oncogene activation in a solid tumor due to an acquired
chromosomal abnormality. This abnormality leads to a chimeric
transforming transcript, RET/PTC, in analogy to the production
of the chimeric protein that follows the 9;22 translocation in
chronic granulocytic leukemia (4). In fact, RET/PTC is origi-
nated by the fusion of two unrelated sequences, a portion of
proto-RET including its tyrosine kinase domain and DJOS170,
which provides the 5' end promoter region (11).
The transforming sequence RET/PTC has been identified
in -25% of patients with papillary thyroid carcinomas (12,
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FIG. 3. Southern blot analysis of normal (lanes N) and tumor (lanes T) DNA of patient 1 and of NIH 3T3-untransfected (lanes NIH) or
transformed (lanes NIH-Ti) by the tumor DNA of patient 1. After EcoRI digestion, the DNAs were hybridized to the molecular probes described
in Fig. 2 for patient 2: RET probe (A), DIOS1 70 probe (B), and 5' end of proto-RET probe (C). The latter probe does not recognize specific
sequence either in control or in RET/PTC-transfected NIH 3T3 (NIH-Ti) because this region of proto-RET was truncated in the
RET/PTC-transforming sequence formation. (D) Northern blot analysis of transcripts from a neuroblastoma cell line (lane SK-N-SH),
representative of proto-RET mRNAs (10), NIH 3T3 transformed by the DNA from patient 1 metastatic tissue (lane NIH-Ti) and from NIH-3T3
transformed by cloned and sequenced RETIPTC (lane NIH-T2) (11).
13). Recently, Ishizaka et al. (19) have cloned the same
hybrid sequence, generated by DJOS170 and RET fusion,
Eco RI
N
_
I
C T z z
NI- I-
I I
C T z z
RET
EcoRI
(371)
351 352
19 213 34512- 306 bp
485 502
-174bp-!
A 132 bp=
B
FIG. 4. PCR amplification of the fusion cDNA fragment containing
the DOSJ170-RET breakpoint region, as deduced from the partial map
(Lower) derived from RET/PTC sequence (11). (Upper) The starting
RNAs were from a control human melanoma cell line (lanes C), a
lymph-node metastatic specimen from patient 1 (lanes T), NIH 3T3
transformed by the tumorDNA ofpatient 1 (lanes NIH-Ti), and NIH 3T3
transformed by the sequenced RET/PTC (lanes NIH-T2). Bacteriophage
0X-174 RF DNA-HaeIII digests were used as molecular size markers.
from a papillary thyroid carcinoma cell line. These findings
make RET/PTC the most frequently detected oncogene in
human solid tumors, immediately following the detection of
oncogenes belonging to the RAS gene family.
A pathogenetic role of RET/PTC in papillary thyroid
carcinomas is supported by the observation of its activation
in both primary and metastatic tumor lesions and not in the
normal DNA of the same patient (11-13). In addition, the
normal thyroid epithelium does not express RET-related
transcripts (11), and an inappropriate RET expression driven
by a mouse mammary tumor virus promoter/enhancer has
been recently reported (20) to form mammary and salivary
gland adenocarcinomas in transgenic mice.
The present data, reporting a paracentric inversion of the
long arm of chromosome 10, allow us to propose the model
depicted in Fig. 1B for the generation of the RET/PTC-
transforming sequence. The molecular analysis also supports
the model by identifying the rearrangement bands due to the
fusion event reciprocal to that generating RET/PTC. Because
we have determined the gene order on lOq as cen-RET-
DJOSJ70-qter (15) and because the inversion resulted in the
generation of functional chimeric transcripts, we can deduce
that RET and DIOS]70 are normally transcribed on opposite
DNA strands. In the model we have considered only the
possibility of RET-DJOSJ70 divergent transcription. How-
ever, our data cannot exclude the opposite possibility of
convergent transcripts. The most relevant consequence of
this model is that every case ofRET/PTC formation in tumor
cells should involve a chromosomal inversion. It has been
recently reported (21) that the genes of the immunoglobulin
K light chains are assembled by somatic recombination that in
some instances can include a megabase-sized chromosomal
inversion, demonstrating that in physiological conditions
such an event can lead to a functional product.
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